2018 RNAi Roundtable: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type 1
Conference Call Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc Conference call or earnings call will be held on Aug 15, 2018 via an 800 number (toll-free). During the earnings conference call's session Alnylam Pharmaceuticals Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Alnylam Pharmaceuticals Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
We are a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. We believe that drugs that work through RNAi have the potential to become a broad new class of innovative medicines, and that this potential new drug class is similar to the opportunity created with other major biological discoveries such as recombinant DNA and monoclonal antibodies. Using our intellectual property and expertise, we are developing what we believe to be a reproducible and modular platform to develop RNAi therapeutics for a variety of human diseases.Read more Conference Call